AU Patent

AU2022317820A1 — Methods and compositions for treating cancer

Assigned to F Hoffmann La Roche AG · Expires 2023-12-14 · 2y expired

What this patent protects

This invention relates to methods and compositions for use in treating cancer in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1 ) and lymphocyte activation gene-3 (LAG3).

USPTO Abstract

This invention relates to methods and compositions for use in treating cancer in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1 ) and lymphocyte activation gene-3 (LAG3).

Drugs covered by this patent

Patent Metadata

Patent number
AU2022317820A1
Jurisdiction
AU
Classification
—
Expires
2023-12-14
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.